chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report was received from a medical assistant regarding a 61 years old female patient. On 11-NOV-2005, the patient was vaccinated with a dose of PNEUMOVAX 23 (lot #, route, dose and expiry not reported). Concomitant medications were not reported. On 11-NOV-2005, the patient experienced fever when she received PNUEMOVAX 23. No treatment information was reported. The outcome of fever was unknown. It was unspecified if the patient had sought medical attention. This is 1 of 2 reports regarding the same patient. Additional information is not expected.
Information has been received from a physician concerning a 14 year old female patient who 9 years ago in January 2002, was vaccinated with a dose of VARIVAX (Merck) (Lot #, expire date and route not reported). Physician stated that on an unspecified date, the patient experienced a full blown case of varicella. At the time of the report, patient's outcome was unknown. Additional information has been requested.
Five days after receiving the Moderma Covid Vaccine,  welts began appearing on various body parts.  Some the size of quarters, some smaller. Itchy, red, raised skin.  As of this date (March 1) they have appeared and remain on my inner thigh, stomach area, chest, and top of foot.
44 yr old female who received her anthrax vaccination SC over her right lower triceps region on 10/18/04. She noted redness, tenderness and swelling at the vaccine site that evening. The local reaction continued to increase in size and intensity, so on 21Oct she went back to the immunization clinic and was told that it was a normal reaction.  By the week end (23 and 24 Oct), the site was very painful and hot to the touch. She also experienced swelling and stiffness of her right hand and found it difficult to make a fist. She took Tylenol throughout the weekend and applied ice packs to the site. She also began experiencing generalized body aches and headaches. On 27Oct, she sought evaluation at the ER. She was diagnosed with cellulitis, started on Clindamycin and given a consult to Allergy and Immunology for evaluation of vaccine adverse reaction. On 10/29/03, she complains of tenderness, redness, swelling and warmth at vaccine site. She continues to have some swelling of the right hand when dependent, and her headache has continued almost constantly since the weekend. (She describes the headache as being different from a regular headache; it is like an electric shock across the frontal area with no associated symptoms except phonophobia; she has been taking Motrin which seems to help a little.) She denies fever, numbness or tingling in arm or hand, fatigue or joint pain. Follow-up Information: An initial VAERS report was filed on this patient in June 2005 by a healthcare provider at the vaccine Healthcare Center. This service member continues to experience headaches, but the swelling of right hand has resolved and the pain of her right hand is diminished. Here is a note after a telephone conversation on 12/4/06: Spoke to patient who is now retired. She has not been evaluated recently for her migraine headaches, but she continues to have episodes about 3 times/month. She is using Imitrex pills and nasal spray for severe headaches. She had also been taking Midrin pm, but when she ran out, she started taking her nortriptyline, which she was able to tolerate after a couple of weeks; noted she had less frequent headaches while taking, but has now run out of that too. Urged to follow up with PCM to resume nortriptyline use. VA disability determination for migraines is still pending. Had history of swollen and painful right hand; has been using paraffin soaks for hand pain pm with improvement; swelling has resolved. Has not taken the influenza vaccine this year.
Started exp. central chest tightness and on site of sternum; interment; started about 5-10 min. after vaccination; last 30-60 seconds - tightness - however didn't feel short of breath or light-headed. It would come about a min. or two apart. Lasted for 30-45 min. Resolved on it's own. They transported me to ER. They listened to lungs; did not hear wheezing. My blood pressure was elevated a little initially - 130/90 which is elevated for me. And then it went back down within that 45 time frame. I was monitored there in ER. They wanted to monitor me in the ER so logistical reasons. Did not have rash or light headness. Released after an hour of observation and symptoms had resolved. Then went back to work. The place of vaccination and ER were the same hospital.
This initial spontaneous case, was received from other health professional (registered nurse) on 01-Jun-2017 and concerns students in an academic campus, who received flu vaccine. This case deals with second of 23 reports. From 03-Oct-2016 to 04-Oct-2016, 176 students were vaccinated with FLUCELVAX in the total of 258 students in the campus. In the spring of 2017, an outbreak of the flu occurred and lasted for approximately 10 days. The reporter stated that, from 13-Apr-2017 to 18-Apr-2017, they treated 22 students with flu and among them 5 students had the vaccine on campus. In the beginning of 18-Apr-2017, they treated another 23 students with flu symptoms and only 3 of those had not received the flu vaccine. The students were tested positive for influenza A via rapid flu test with nasopharyngeal swab. This case concerns a 17-year-old patient of unspecified gender. On 03-Oct-2016, the patient received FLUCELVAX QIV (dose, route of administration and anatomical location: not reported, batch number: 185888, expiration date: 31-May-2017). On 16-Apr-2017, the patient was tested positive for influenza A via rapid flu test with nasopharyngeal swab (characterized as vaccination failure). Based on the investigation performed, it can be concluded that FLUCELVAX 185888 was manufactured in compliance with the approved internal procedures and in accordance with the quality requirements. No evidence was found that the LOE complaint was the result of the Fill Finish or Bulk manufacturing process and no trends were identified for the batch number 185888, or any other FLUCELVAX QIV batches from the 2016-2017 FLUCELVAX Commercial season. Therefore no internal root cause could be confirmed. Outcome of influenza A virus infection and vaccination failure was not reported. The reporter did not assess the seriousness and did not provide the causality between events and suspect vaccine. The reporter stated that, the students received flu vaccine had less severe symptoms than those who had not received the flu vaccine. Batch review report (QAIR number: 1022277) received from quality assurance department on 29-Jul-2017: QA investigation results were updated. Narrative amended accordingly. Non-significant case correction received on 10-Aug-2017: The narrative was corrected.
11/29/00, left arm became swollen, hot, stiff and painful. 11/30/00, symptoms increased. Telephone call to MD; started taking Benadryl 25mg po every 8 hours. (Throbbing and itching). 12/1/00, MD says due to increased spreading of swelling and rash, prescribed Cefadroxil 500mg BID X 7 days. 12/5/00, taking antibiotics and symptoms have improved.
Patient woke up with a sore, swollen arm that was warm to the touch. There were no other effects reported.
Sore lower throat/trachea on outsidenot really on inside; Hurts whencoughing.; Voice sounds gravel-y and a little hoarse; This is a spontaneous report received from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: ER8732) via an unspecified route of administration on left arm on 22Mar2021 at 16:30 (at the age of 44-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies. Concomitant medications included spirolactone 50 mg (MANUFACTURER UNKNOWN), vitamin D (MANUFACTURER UNKNOWN), unspecified multivitamin (MANUFACTURER UNKNOWN) all for unknown indication from an unknown date. The patient did not receive any vaccination within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, patient had not been tested for COVID-19. On 24Mar2021 at 12:00, the patient had sore lower throat/trachea on outside not really on inside. started at noon and worsened over afternoon. Felt like the patient need to cough. Hurts when coughing. Hurts when press on throat. Voice sounds gravel-y and a little hoarse. Patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events sore lower throat/trachea on outside not really on inside, hurts when coughing. and voice sounds gravel-y and a little hoarse was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
loud ringing in right ear, went to sleep then awoken by loud ringing and unable to hear out of right ear
Red, swollen itchy welts on arms and left side of chest; took Benadryl tablets (2) and applied Aveeno itch ointment.
tongue tingling Narrative: "Fullness back of neck" 5 min after vaccination 2nd. Hx uncontrolled hypertension on no meds. Observed 30 min. 12:24 182/132, hr 92. 12:27 185/113 mild tongue tingling. 12:50 176/117 tingling resolved. PCP for f/u chronic htn. Asymptomatic HTN.
Patient monitored for 15 minutes after covid vaccine injection - patient stated she felt a little dizzy Doctor went in room to see the patient - patient stated she felt ok and patient was discharged home
Headache; This is a Spontaneous report from a contactable Consumer. This consumer reported for 15-year-old male patient (reporter's son). A 15-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: Solution for injection, Batch/Lot Number: EW0178), dose 2 via an unspecified route of administration, administered in arm left on 12Jun2021 as dose 2, single for COVID-19 immunization, (age at the time of vaccination was 15-year-old). The patient medical history and concomitant medications was not reported. Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: Solution for injection, Batch/Lot Number: Unknown), dose 1 via an unspecified route of administration, administered on 22May2021 as dose 1, single for COVID-19 immunization, (age at the time of vaccination was 15-year-old). On an unspecified date the reporter stated, I have the question, my son (consumer) had his second (Pfizer) vaccine (unspecified vaccine) yesterday (12 Jun 2021) and he has headache (overnight). I just wanted to know whether I could give him something worth medicine (treatment) for the headache." The patient did not receive any treatment for the above event. Outcome of the event was reported as unknown.   Information on Lot/Batch number was available. Additional information has been requested.
Injection site is very swollen, red, hot & itchy.   Began 8 days after vaccine.  No treatment at this time.  Will call primary doctor tomorrow.
Pain in left arm  was followed a few hours later by chills, body aches, diarrhea, nausea, severe headaches, mild fever, and some fatigue.  Then about 36  hours after vaccination I had radiating back pain in my mid-upper back and severe indigestion (I have never had indigestion before) and a somewhat heavy feeling in chest when breathing .  Approximately 48 hours after the vaccination almost all symptoms subsided, just a sore arm remains.
Sharp chest pain occurring every 1-5 minutes from 7:00pm to 9:30pm, roughly 24 hours post-vaccination.  Pain was a non-radiating, sharp, stabbing pain in the center of the chest.   Tums taken at both 7:30pm and 9:00pm did not alleviate pain.  Symptoms had resolved upon waking up the next morning.  I was not woken up by any symptoms throughout the night.
Within 24 hours, developed severe shoulder pain, subjective fevers with redness and warmth around the injection site. Pain inhibited sleep. Was treated with NSAIDS and ice. Suspect bursitis or other shoulder injury. Pain is only slowly improved on day 5 after the vaccine.
he had an anaphylactic reaction about 10 to 15 minutes after the vaccine; nose became completely blocked. He complained of not being able to breathe through his nose and his nose appeared swollen; nose became completely blocked. He complained of not being able to breathe through his nose and his nose appeared swollen; nose became completely blocked. He complained of not being able to breathe through his nose and his nose appeared swollen; Initial information received on 30-Apr-2019 regarding an unsolicited valid serious case received from a consumer/non-health care professional.  This case involves a male patient of unknown age for whom it was reported that nose became completely blocked. He complained of not being able to breathe through his nose and his nose appeared swollen, he had an anaphylactic reaction about 10 to 15 minutes after the vaccine MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA].  The patient has Milk allergy.   The patient's past medical treatment(s), vaccination(s), concomitant medication(s) and family history were not provided.  No other vaccines was given.  On an unspecified date of June-2018, the patient received a first dose of suspect MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE lot number not reported via unknown route in deltoid nos.  On an unknown date in Jun-2018, 10 to 15 minutes after the vaccination the patient had anaphylactic reaction with nose became completely blocked (nasal congestion) and complained of not being able to breathe through his nose (dyspnoea) and nose appeared swollen (nose oedema). Anaphylactic reaction was assessed as medically significant.  The patient was taken to doctor's office. The reported wanted to confirm if Menactra contains components derived from milk, as the patient had milk allergy.  (Other relevant tests included no lab data.)  Final diagnosis was anaphylactic reaction and breathing difficult.  The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) and nebulizer.  The outcome of the events was reported as recovered on an unknown date.  Information on the batch number was requested.  List of documents held by sender: none.; Sender's Comments: This case involves a male patient who experienced anaphylactic reaction and breathing difficulty after vaccination. Anaphylactic reaction was assessed as medically significant. The patient's past medical history included Milk allergy. Time to onset is compatible with the role of vaccine. More details regarding patient's previous vaccination history, history of similar episode, etiological workup and investigation reports to identify alternative etiology are needed for complete assessment of the case. Based on the available information the role of vaccine cannot be assessed.
Pt was given undiluted Pfizer 5-11 kids vaccine. (0.2ml). No apparent side effects. Mother was notified by staff of the error and to watch for any side effects.
This spontaneous report was received from a registered nurse referring to a 16 year old male patient. The patient's concomitant medication, pertinent medical history, concurrent conditions, drug reactions or allergies were not reported. On 03-OCT-2017, the patient was vaccinated with either GARDASIL lot # N000326, expiration date 14-OCT-2019 or GARDASIL 9 lot # N000326, expiration date: not reported (strength, dose, dose number and route of administration were not provided) for prophylaxis which were improperly stored (incorrect product storage). This is one of several reports received from the same source.; Sender's Comments: US-009507513-1709USA008666:
Generalized red rash and itching, a lot of Itching all over the body.
10/06/06 pt came in after receiving PCV and Hep B on 10/04/06. Pt reported pain and swelling of right deltoid. On exam pt had swelling, bruising and some red 1.5cm induration, bumps, pt notes diffuse myalgia.
4 hours post injection: sore injection site, fatigue 8 hours post: extreme pain at injection site and extreme fatigue 20-36 hours post: extreme pain at injection site , extreme fatigue, low grade fever, nausea, extreme chills, dizziness 36 hours post: cough, clogged sinuses, extreme headache 48 hours post: slight fatigue, slight cough, slight runny nose, moderate pain at injection site
painful swelling of the lymph node in my right armpit after my second dose (which was in my right arm); painful swelling of the lymph node in my right armpit after my second dose (which was in my right arm); This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER87729) via an unspecified route of administration in the right arm on 09Apr2021 at 13:30 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included depression (reported as depressing), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), attention deficit disorder (ADD) and scoliosis. The patient had sensitivity to nickel (nickel allergy) and pollen allergy (pine pollen and cottonwood pollen). The patient had received other medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 19Mar2021 at 13:30 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021 at 06:00, the patient experienced painful swelling of the lymph node in her right armpit after her second dose (which was in her right arm). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events painful swelling of the lymph node in right armpit after second dose (which was in right arm) was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
This spontaneous report was received from a physician via company representative and refers to a 89-year-old female patient with high cholesterol. Information about the patient's dug reaction or allergies were not reported. On 21-JAN-2018, the patient was vaccinated with ZOSTAVAX, vaccine dose, to prevent shingles (lot#, route of administration, anatomical location and expiration date were not reported). Concomitant therapies included gabapentin, omega-3 marine triglycerides, TYLENOL WITH CODEINE and aspirin. On 02-FEB-2018, the patient was diagnosed with shingles. She sought medical attention and saw her physician (date was not reported). However, it was unknown if the patient received any treatment for the event. The outcome of herpes zoster was reported as not recovered. Causality assessment was not provided.
Hospitalized (9.27.21) and ED visits;  COVID-19 positive (9.17.21);  fully vaccinated    Admission Date: 9/27/2021 Discharge Date: 10/2/2021 DISCHARGE DISPOSITION: Discharge to home DISCHARGE CONDITION: Stable HOSPITAL COURSE: a 65 y.o. male admitted to the hospitalist service on 9/27/2021 with COVID-19 infection and related symptoms including progressive SOB, fatigue, diarrhea, body aches.    PMhx significant for bipolar disorder, psychotic behaviors, depression, OSA, obesity, DM II, essential HTN, seizure disorder.    Pt with suicidal ideation on presentation. He required video monitoring given suicidal ideation during stay, but this was discontinued after formal social work evaluation.    Pt was seen by PT/OT during stay and SAR was recommended.  He was felt stable for discharge to subacute rehabilitation on 10/02/2021.  He has continued cough, but was breathing comfortably on room air.  Will continue with antitussive therapy at discharge, including Tessalon Perles and Robitussin DM, as well as 3 more days of oral Decadron.  He should follow up with his PCP in 1 week.
PATIENT HAD GOTTEN HIS 1ST DOSE OF PFIZER 2 DAYS AGO AND CAME BACK TO THE PHARMACY TODAY CLAIMED THAT HE HAS A DARK RED LINE OF REDNESS TRAVELED ALONG HIS BLOOD VEIN TOWARD THE BICEP FROM HIS SHOULDER (INJECTION SITE), NO RASH, NO  ITCH, NO SWELLING BUT  A LITTLE WARM. THE REDNESS LINE IS FADING OFF NOW.
2 minutes after receiving the vaccine pt began to feel itching to bilaral arms and left rib area. Itching progressively became worse. 50 mg benadryl given. No relief.  16 min after receiving vaccine pt complained of lips swelling and throat tightening and feeling swollen. Lips swollen. 0.3 mg epi auto injector given in left thigh. 911 called. 1-2 minutes after epi throat felt less swollen, itching began to decrease. Pt remained alert and oriented x3 and no evidence of respiratory distress. Ambulance arrived. pt left on stretcher
Patient is fully vaccinated and boosted 10/9/2021. COVID + 1/24/2022.  79 yr old male COPD and chronic respiratory failure. He presented to ER with respiratory distress, shortness of breath, cough pulse Ox  dropping to 70s.He tested positive for COVID and chest xray showed right pneumonia.Admitted for acute hypoxic pneumonia. Treatment:  IV fluids, IV antibiotics, high flow oxygen.  Given remdesivir, decadron, lovenox. Discharged home.
Coworker experienced migraines; This spontaneous case was reported by a health care professional and describes the occurrence of MIGRAINE (Coworker experienced migraines) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was reported by the reporter.     On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced MIGRAINE (Coworker experienced migraines). At the time of the report, MIGRAINE (Coworker experienced migraines) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided by the reporter.  No treatments were provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 11-Jun-2021: TCR received and included information to confirm that reporter did not receive the Moderna vaccine and had only mentioned a coworker that received Moderna with an AE of migraine.  Case updated to reflect this information.
Approximately 60 hours after I woke up with my tongue swollen. I felt faint and could not concentrate well. I took 2 Benadryl and my EpiPen. I used Benadryl for the next 72 hours. Today is 8 days since the injection and the injection site is becoming warm to the touch, hard and itchy.
Ever since he had shots in both arms he has been having burning in his muscles and in the axilla. Last night upper thighs were hurting and very sensitive. Says both legs and thighs are numb. Today hurting a little lower than the thighs. No headache or fever. Had anorexia over the past weekend and continued on Monday and Tuesday.
Temp 103, swelling of lips, hives, wheezing Pt presented to clinic on 09/24/2010 with hives and wheezing and received three day dose of prednisolone and hydrocortisone cream for hives
2nd dose of Pfizer - Pediatric dose given instead of adult dosing. No reaction.
Acute on chronic diastolic heart failure - Echocardiogram 12/19/2021 revealed normal left ventricular systolic function, moderate aortic stenosis without significant change compared to echocardiogram performed on 12/14/2020.  Patient received IV laxis during hospital stay and was subsequently transitioned to oral laxis at discharge.  ED visit to hospital admission within 6 weeks of receiving the COVID vaccine.
1/15/2021 @5:00 Red at the injection site unbearable pain, swelling and hot it lasted 4-6 weeks and very exhausted